Form 4: Nurix Legal Officer Sells Shares Under 10b5-1 Plan

Nurix Therapeutics' Chief Legal Officer, Christine Ring, sold 37,600 shares of common stock for a weighted average price of $17.0664 after exercising options.

Summary

• Christine Ring, Chief Legal Officer of Nurix Therapeutics, Inc., executed a planned transaction on November 24, 2025.
• She acquired 37,600 shares of common stock by exercising employee stock options at an exercise price of $1.86 per share.
• Immediately following the option exercise, she sold all 37,600 shares of common stock at a weighted average price of $17.0664 per share.
• The sale price ranged from $17.00 to $17.26 per share.
• These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan.
• Following these transactions, Christine Ring beneficially owns 50,897 shares of common stock and 16,163 employee stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While it's an insider sale, it was pre-planned under a 10b5-1 plan, which mitigates negative interpretations. The significant profit from the option exercise is a positive for the insider.

Positives

• The transactions were executed under a Rule 10b5-1 trading plan, indicating a pre-scheduled, non-discretionary sale.
• The sale price of $17.0664 per share is significantly higher than the option exercise price of $1.86, indicating a profitable transaction for the insider.

Negatives

• An insider sale, even if pre-planned, can sometimes be perceived negatively by the market as it reduces the insider's direct equity stake.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders may observe a reduction in direct equity ownership by a key executive, which could be interpreted in various ways, though the 10b5-1 plan mitigates concerns about opportunistic selling.

Key Dates

Recommendation

This Form 4 filing details a routine, pre-planned insider transaction (option exercise and sale) by the Chief Legal Officer. The transaction was executed under a Rule 10b5-1 plan, which suggests it was not based on new material non-public information. While an insider sale reduces direct ownership, the pre-planned nature and the significant profit realized from the option exercise do not provide new fundamental information to warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate as this filing alone does not present a strong case for buying or selling.

Keywords

Nurix Therapeutics, NRIX, Form 4, Insider Trading, Stock Option Exercise, Share Sale, Christine Ring, Chief Legal Officer, 10b5-1 Plan, Biotechnology